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STUDI PUSTAKA
ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers and the major cause of cancer death in Asian
countries. HCC typically develops in patients with chronic liver disease and cirrhosis. HCC surveillance with α-
fetoprotein (AFP) and ultrasonography has been recommended for persons with cirrhosis. However, AFP level is
insensitive for the early detection of HCC, and ultrasonography is expensive and operator dependent. Clearly, there is
a need for novel strategies for the early detection of HCC. The ideal biomarker assay for HCC would be sensitive,
specific, noninvasive, reproducible, inexpensive, and acceptable to patients. We performed a review of the literature
(2001–2009) of traditional and novel serum markers for hepatocellular cancer. Several biomarkers, such as AFP-L3,
des-gamma carboxyprothrombin (DCP), golgi protein 73 (GP73), glypican-3 (GPC3), squamous cell carcinoma antigen
(SCCA), transforming growth factor-βb1 (TGF b1), insulin-like growth factor-II (IGF-II), insulin-like growth factor-binding
protein-2 (IGFBP-2), human cervical cancer oncogene (HCCR), hepatocyte growth factor (HGF), KL-6 and α-acid
glycoprotein (AAG) are promising, but none of these markers has been validated for clinical use. Limitations of the
current literature include inadequate sample size, heterogeneity in biomarker assay methods and result reporting,
limited analysis of demographics and cause of liver disease as covariates in the expression of these markers, and a
scarcity of longitudinal studies evaluating the ability of biomarkers to detect preclinical disease. A new generation of
HCC serum markers awaits validation in properly controlled clinical studies.
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ABSTRAK
Hepatocellular carcinoma (HCC) atau kanker hati adalah salah satu dari kanker yang paling umum dan menjadi
penyebab utama kematian di negara-negara Asia. HCC biasanya berkembang pada pasien dengan penyakit hati kronis
dan sirosis. Pengamatan HCC pada pasien sirosis biasanya dilakukan menggunakan α-fetoprotein (AFP) dan
ultrasonografi. Akan tetapi, sensitivitas AFP untuk deteksi HCC sangat rendah, sedangkan penggunaan ultrasonografi
cukup mahal dan sangat tergantung pada keahlian operator. Hal inilah yang menjadi ide dasar tentang perlunya
mencari suatu strategi baru (biomarker baru) dalam mendeteksi HCC secara dini. Biomarker yang ideal harus lebih
sensitif, spesifik, noninvasif, murah, dan dapat diterima oleh pasien. Berdasarkan tinjauan literatur yang kami lakukan
(2001-2009), dilaporkan beberapa penemuan biomarker baru yang cukup menjanjikan, seperti AFP-L3, des-gamma
carboxyprothrombin (DCP), golgi protein 73 (GP73), glypican-3 (GPC3), squamous cell carcinoma antigen (SCCA),
transforming growth factor-β1 (TGFβb1), insulin-like growth factor-II (IGF-II), insulin-like growth factor-binding protein-2
(IGFBP-2), human cervical cancer oncogene (HCCR), hepatocyte growth factor (HGF), KL-6 and α-acid glycoprotein
(AAG). Akan tetapi, penggunaannya secara klinis atau uji validasi belum pernah dilaporkan. Beberapa kendala dan
keterbatasan yang dilaporkan dalam penemuan biomarker ini antara lain jumlah sampel yang digunakan kurang
memadai, metoda analisis yang beragam (heterogenity), terbatas pada wilayah tertentu, predictive analysis biomarker,
dan masih sedikitnya studi longitudinal untuk mengevaluasi kemampuan biomarkers dalam mendeteksi penyakit pada
taraf preklinik. Uji klinik dan metoda validasi yang tepat saat ini menunggu lahirnya suatu generasi biomarker baru
untuk pasien HCC. 
Kata kunci: Hepatocellular carcinoma (HCC), biomarker, metoda pengujian
Correspondence:
Indra Bachtiar Ph.D,
Mochtar Riady Institute
for Nanotechnology
Jl. Boulevars Jend.
Sudirman 1688
Lippo Karawaci,
Indonesia, 15811
Phone: +62-21-5421-
0123 ext. 8108
Fax. : +62-21-5421-0110
Email:
ibachtiar@mrinstitute.org
Serum Biomarkers For Hepatocellular
Carcinoma (Short Review)
INDRA BACHTIAR, ANDI UTAMA, SUSAN TAI
Mochtar Riady Institute for Nanotechnology
72 Indonesian Journal of Cancer Vol. III, No. 2      April - Juni 2009
INTRODUCTION
Primary Hepatocellular carcinoma (HCC) is one of themost common malignancies in the world. Because of
the global pandemic of hepatitis B and C viral infections,
the incidence of HCC is rapidly increasing in Asian and
Western countries, and this trend is expected to continue
for the next 50 years because of the long latency between
infection and the development of HCC. The prognosis of
advanced HCC remains poor and novel treatment and
diagnosis strategies are urgently needed.1 Currently, the
only available tools for HCC surveillance are testing for
serum α-fetoprotein (AFP) level and hepatic ultra-
sonography. However, AFP level has poor sensitivity and
specificity for HCC and ultrasonography is operator
dependent and limited in its ability to differentiate HCC
from such non-neoplastic lesions as regenerative nodules.
Newer methods for the early detection of HCC are
needed in the form of either biomarkers or radiological
tests. Biomarkers are defined as indicators of cellular,
biochemical, molecular, or genetic alterations by which
normal or abnormal biological processes can be
recognized.2
The ideal marker for HCC would be specific for HCC
and not detected in premalignant liver disease (ie,
cirrhosis regardless of the cause). It should be sensitive,
enabling detection of HCC at an early stage, when
curative treatment is possible. The marker should be
easily measurable, and the test should be reproducible,
minimally invasive, and acceptable to patients and
physicians. There have been many reports of novel
biomarkers for HCC.3 When searching PubMed with a
combination of the key words “hepatocellular carcinoma”
and “biomarkers,” 2794 reports were identified in
2000-–2009. Recent developments of gene-expression
microarrays, proteomics, and tumor immunology permit
thousands of genes and proteins to be screened
simultaneously. With the growing application of these
techniques, it is anticipated that there will be an
explosion of new biomarkers for cancer screening,
including HCC, in the next decade. This review sum-
marizes recent studies of the specific molecular markers
in diagnosis of HCC.
SINGLE MARKERS
α-Fetoprotein
Alpha-fetoprotein (AFP) is an oncofetal glycoprotein
of unknown function that is present at increased levels in
sera of patients with cirrhosis and HCC.  So far AFP, the
only serological marker commonly used in diagnosis, has
failed to be a reliable marker mainly because it shows
poor sensitivity, ranging from 39% to 65% and a
specificity ranging from 76% to 97%.4 This high variability
is because different cutoffs are used in the different
studies and also because these data were mainly
obtained from retrospective studies. AFP seems to be
reliable at values over 400 IU/ml, but the percentage of
patients with such high levels is very small; this represents
one of the most important limits of this marker.
AFP-L3
The fucosylated variant of the AFP glycoprotein,
having a high affinity of the sugar chain to Lens culinaris
(AFP-L3), has been proposed to be more specific than
AFP for HCC diagnosis. The percentage of AFP-L3 was
calculated as the ratio between AFP-L3 and total AFP
using lectin-affinity electrophoresis, and the intensity of
the band analyzed by a densitometer. Initially, AFP-L3 was
proposed as a better marker of HCC, having 55.3%
sensitivity and 93.9% specificity, at a 15% cut-off value.5
In another study, a better sensitivity and specificity (75%
and 83%) led to a reliable diagnostic accuracy, but using a
35% AFP-L3 cut-off value.6 More recently, using a 15%
cut-off value, a sensitivity of 96% and specificity of 92%
have been reported. However, these very promising
results were not reproduced in another study, in which the
sensitivity and specificity were 36.1% and 93.4%,
respectively, using a 10% AFP-L3 cut-off, versus 30.9%
and 99.5% using a 15% cut-off. In any case, the diagnostic
accuracy was still poor: 53.2%.7 The inconsistency of the
data is very likely explained by the reading assay used to
determine the AFP-L3 percentage, since it is very difficult
to standardize the conversion of a qualitative technique
like immunoblotting into a quantitative technique by
densitometry.
Des-gamma Carboxy Prothrombin (DCP)
DCP is an abnormal prothrombin lacking carboxy-
lation of the 10 glutamic-acid residues in the N-terminus,
and is the result of an acquired post-translational defect
of the prothrombin precursor in HCC cells, and therefore
used as HCC marker. DCP, also known to be induced by
Vitamin K absence or antagonist-II (PIVKA-II), does not
have any biological coagulative activity. In 1984, Liebman
first reported higher DCP in patients with HCC and also
higher levels in patients with recurrence of the disease
after surgical resection, suggesting the use of DCP as an
HCC marker. After that, DCP was investigated in several
studies but very different results were obtained de-
pending on the cut-off value used. Currently, 40mAU/ml is
the cut-off most widely adopted and based on this value,
sensitivity ranges between 48% and 62% and specificity
between 81% and 98%.8 In the same studies DCP did not
appear markedly better than AFP, which had a sensitivity
of 40–54% and specificity of 88–97%. The use of DCP in
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combination with AFP is also suggested by the fact that
the two markers are not correlated. In other studies, it has
been reported that DCP seems to be particularly related
to the intrahepatic invasiveness of the tumour in
particular toward the portal vein.9 In conclusion, DCP is
more reliable than AFP as a prognostic tool for predicting
the clinical outcome of patients with HCC, rather than as a
diagnostic tool for early detection of the cancer. For this
reason DCP is not an adequate diagnostic marker.
Golgi Protein 73 (GP73)
GP73 is a resident Golgi protein, shown to be up-
regulated in HCC patients. Marrero reported a sensitivity
of 69% and a specificity of 75% in HCC versus cirrhotic
patients, using 10 relative units as cut-off, calculated by
densitometric scanning of immunoblotting.10 Although
this is a promising study, more investigations are required
to confirm these data and clarify the role of this marker in
detecting early cancer, considering that these data seem
better than those for AFP but not dramatically so.
However, it is very unlikely that this marker could be used
in clinical practice because the technique used to quantify
it does not make the molecule suitable as a routine
biomarker, since it does not fit the ideal technical criteria
defining a reliable clinical marker for large-scale use in
diagnosis.
Glypican-3 (GPC3)
GPC3 is an oncofoetal protein, being a member of the
glypican family of heparin sulphate proteoglycans. GPC3
has been reported to be down-regulated in breast cancer,
ovarian cancer and lung adenocarcinoma but upregulated
in HCC. GPC3 has been mainly investigated at the tissue
levels, although some studies have reported the presence
of GPC3 in the sera of about 50% of HCC patients but
absence in healthy subjects.11 In HCC, GPC3 has been
shown to stimulate growth forming complexes with
Wingless-type MMTV (Wnt) interaction site family. No
systematic data are available concerning its sensitivity
and specificity, furthermore the use of this marker mainly
in histological procedures hampers its use in surveillance
programs and in the clinical setting.
Squamous Cell Carcinoma Antigen (SCCA)
SCCA is a member of the high molecular weight family
of serin protease inhibitors (serpins). Two different
isoforms encoded by two highly homologous genes,
SCCA1 and SCCA2, have been identified. Both proteins
are physiologically expressed in the supra basal layer of
multi-stratified squamous epithelium. SCCA has been
detected in a number of different multi-stratified
epithelium-derived malignancies, including the cervix,
lung, head and neck. Pontisso et al. were the first to report
the expression of SCCA variants in HCC tissues at the
protein and translational levels.12
In a subsequent study, a strong difference was
reported between SCCA expression in HCC and
peritumoural tissues in the same patients, suggesting the
usefulness of this marker either in immuno histochemical
diagnosis of HCC, or in the search for micrometastases.
The detection of SCCA in HCC tissues is quite surprising
since no squamous epithelial cells are present in the liver,
although they are in other epithelial malignancies with
which the liver shares a common embryogenic origin. A
fascinating hypothesis, that still needs to be demons-
trated, is that SCCA could represent a biological
fingerprint of the dedifferentiation that commonly occurs
in HCC, like AFP production. Furthermore, SCCA has
been detected at higher levels in the sera of HCC than
cirrhotic patients, although no clear correlation was found
between tissue and serological levels, likely because
SCCA is present at the cytosol level, not being associated
with membrane-bound organelles. Thus, circulating SCCA
is a result of cell lysis rather than of a secretory process.
Nevertheless, SCCA has been used in HCC diagnosis and
yielded a sensitivity of 84.2% and a specificity of 48.9%;
for this reason SCCA seems to be the perfect partner to
be used together with AFP, that has low sensitivity but
high specificity. 
Transforming Growth Factor-β1 (TGFβ1)
TGFβ1 is a multifunctional cytokine with increased
expression levels in HCC cells. Elevated levels of
circulating TGFβ1 have been noted in HCC patients. A
recent report by Song compared TGFβ1 and AFP levels in
patients with small HCCs and cirrhotic controls. TGFb1
was measured using a commercial ELISA for active
TGFβ1. The area under the ROC curve was significantly
higher for TGFβ1 than AFP, suggesting increased
sensitivity for TGFβ1. However, the authors caution that
TGFβ1 levels might increase in cirrhotic patients, due to
its decreased hepatic clearance. This feature might limit
its usefulness in patients with advanced liver disease.
Another concern is the lack of disease-specificity since
TGFβ1 expression is up-regulated in wound healing,
angiogenesis, fibrosis, and extra-hepatic tumors.13
Insulin-like Growth Factor-II (IGF-II)
Members of the family of insulin-like growth factors
are thought to be involved in the pathogenesis of HCC.
Increased hepatic IGF-II levels have been found in humans
and experimental animals with liver cancer. Based on
earlier reports demonstrating IGF-II overexpression in
HCC, Tsai performed two comparative studies of AFP
and IGF-II serum levels in HCC patients and cirrhotic or
normal control subjects.14 IGF-II was quantitated by
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immunoradiometry, and its levels were expressed in
relation to serum prealbumin to account for the effect of
nutritional status on IGF-II serum levels. IGF-II/prealbumin
ratios were increased in HCC patients as compared to
cirrhotic and normal controls. However, the sensitivity,
specificity, and overall diagnostic accuracy of IGF-II (42,
96 and 69%) were inferior to that of AFP (73, 98 and 86%).
Due to its unimpressive performance in these studies and
the confounding metabolic influence on circulating IGF-II
levels, the future of this candidate marker is doubtful.
Insulin-like Growth Factor-Binding Protein-2 (IGFBP-2)
IGFBP-2 is a secretory protein that is involved in
insulin like growth factor signaling. IGFBP-2 is produced
by a wide range of tumor cells, and elevated serum levels
have previously been demonstrated in patients with
prostate cancer. Based on a previous report of IGFBP-2
mRNA over expression in a mouse model of HCC, Ranke
et al. measured IGFBP-2 protein levels in the sera of 50
HCC patients.15 IGFBP-2 levels were increased above the
age adjusted normal values in 37 of the 50 patients. This
increase was not attributable to tumor-induced weight
loss, since it did not correlate with the patients’ body
mass index. In contrast, the serum levels of IGFBP-3 and
IGF-1 – two related IGF signaling proteins that are
predominantly produced by hepatocytes – were low. The
sensitivity and specificity of IGFBP-2 for HCC were not
reported, and remain to be determined in future studies.
Human Cervical Cancer Oncogene (HCCR)
Two splice isoforms of HCCR have been identified.
HCCR-1, a 360 amino acid protein, has the characteristic
features of a membrane protein. The shorter isoform,
HCCR-2, lacks a transmembrane domain and appears to
be located within the cytoplasm. The functions of the two
HCCR isoforms are unknown, although one study
suggested that HCCR-2 may function as an oncoprotein.
Increased levels of HCCR have been detected in
cancerous tissues from breast, kidney, ovary, stomach,
and colon. Yoon and colleagues documented robust
HCCR expression in hepatocellular carcinoma cells
without expression in surrounding cirrhotic tissue.16
HCCR was absent in normal hepatocytes, a surprising
finding in light of the fact that the authors had previously
demonstrated substantial hepatic HCCR mRNA levels in
normal livers. The authors developed an ELISA assay for
the detection of the shared C-terminal domains of HCCR1
and -2 in serum, and reported modest (20–40%) increases
in HCC patients as compared to cirrhotic controls. No
differences were found between normal subjects and non-
cirrhotic patients with chronic hepatitis. In comparison
with AFP, HCCR was slightly more sensitive (78% versus
46%) but similar in specificity and overall accuracy. A
trend towards improved sensitivity for the detection of
small (<2 cm) HCCs (69% versus 46%) did not achieve
statistical significance. Further studies will be needed to
identify the circulating serum form of HCCR, and to
evaluate its clinical utility.
Hepatocyte Growth Factor (HGF)
Hepatocyte growth factor is a multi-functional
cytokine that affects mitogenesis, cell motility, matrix
invasion, and epithelial carcinogenesis. Based on earlier
reports of increased serum HGF levels in patients with
chronic HCV infection, Yamagamim et al. prospectively
collected blood samples from patients with chronic
hepatitis, l iver cirrhosis, and newly diagnosed
hepatocellular cancer.17 Since prolonged storage of
venous blood and repeat freezing and thawing results in
HGF activation by serine proteases and artificially high
measurements, samples were frozen in the presence of a
serine protease inhibitor, and analyzed within 48 h.
Serum HGF levels were significantly higher in HCC
patients (0.53- 0.17 ng/ml) than in patients with liver
cirrhosis (0.38-0.08; p < 0.05) or chronic hepatitis (0.38 -
0.05). Unfortunately, data on sensitivity and specificity of
the HGF assay were not provided. 
The prospective component of the study suggested
that high HGF concentrations were associated with a
significantly increased risk of HCC development.
However, increased HGF serum levels have also been
reported in patients with extrahepatic malignancies
including squamous cell carcinoma of the esophagus and
lymphomas, as well as coronary syndrome, aortic
dissection, pulmonary thromboembolism, cerebral
infarction, and sepsis.18 Additional studies will be needed
to determine whether inflammatory changes rather than
hepatic carcinogenesis are responsible for increased
serum HGF levels in patients with chronic hepatitis and
HCC.
KL-6
Kl-6 (also known as mucin 1 or MUC-1) is a membrane
protein expressed in many epithelial cells. It binds
extracellular pathogens, and is involved in cell signaling
and carcinogenesis. Alterations in KL-6 expression levels,
cellular localization, and glycosylation have been
reported in breast cancer and in patients with
inflammatory lung diseases. Recently, Moriyama et al.
demonstrated KL-6 expression in hepatocellular cancer
cells and elevated KL-6 serum levels in patients with HCV-
related HCC.19 Arase et al. studied serum KL-6 levels in
502 consecutive HCV-positive patients, and found
elevated levels in 20% of HCC cases.20 The performance
of KL-6 (34% sensitivity with a specificity of 80%) was
inferior to that of DCP and AFP, respectively. Despite the
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excellent reported specificity (99%) and sensitivity (87%)
of combined KL-6, DCP, and AFP, the future of KL-6 as an
individual marker of HCC appears doubtful.
α1-acid glycoprotein (AAG)
α1-acid glycoprotein (AAG) is a member of the
lipocalins, a family that shares at least 2 structurally
conserved sequence motifs. AAG is synthesized
predominantly in the liver as a single polypeptide of
41–43 kDa, made up of 183 amino acids, with a
hydrophobic prosthetic group, and a high content of sialic
acid. The biological functions of AAG are poorly
understood; it is an acute phase protein, and its plasma
concentration increase as a response to inflammation is
triggered by cytokines. As a consequence, AAG
concentrations vary in many physiological states (age and
pregnancy) and pathological conditions such as liver
cirrhosis, renal disease, and cancer. Significant increases
of AAG have been found in patients with active lung and
gastrointestinal cancers compared with patients with
inactive disease. Moreover, in patients with colorectal
cancer treated with 5-fluorouracil, AAG correlates with a
response to therapy, with lower AAG concentrations seen
in responding patients and higher AAG concentrations
found in patients with progressive disease. AAG serum
concentration has been suggested as a potential marker
for cirrhosis and hepatocellular carcinoma (HCC).
Recently, Indra et al reported that the combination of
AAG and AFP shows high sensitivity and improves the
accuracy of HCC diagnosis.21
PHASES OF BIOMARKER VALIDATION IN CANCER
SURVEILLANCE
To establish a formal framework to guide the process
of biomarker evaluation and development, a 5-phase
program is used by the Early Detection Research Network
(EDRN) of the National Cancer Institute. These 5 phases
help define criteria to determine the current status of
biomarkers in the published literature, assess how close
these biomarkers are to clinical application, and serve as
a guide for future biomarker development.
Phase 1: Preclinical Exploratory Studies
The aim of phase 1 studies is to identify biological
characteristics unique to HCC that may lead to assays for
future clinical use. For each biomarker studied, the key
question is how well it can distinguish between cases and
controls. Studies in this phase are exploratory in nature
and may use tissue, serum, plasma, or urine. Assays
should be reliable and reproducible. If the biomarker is
measured in a binary scale (present or absent), the true
positive rate and false-positive rate should be determined
to summarize its ability to discriminate between disease
and non disease. If the assay involves continuous
variables, a receiver operating characteristic (ROC) curve
should be used, and an optimal cutoff value that will
differentiate cases from controls should be determined.22
Criteria for selection of a biomarker for further
development have not been established, although it has
been suggested that the area under the ROC curve be
used for ranking biomarkers. This review focuses on
biomarkers that can be detected in serum because the
clinical utility of any biomarker assay is dependent on the
use of readily available biological samples.
Phase 2: Clinical Assay and Validation
The aim of phase 2 studies is to identify biomarkers
that can distinguish subjects with cancer from those
without cancer. An important aspect of phase 2 studies is
to identify biomarkers that can detect early-stage cancer;
therefore, the specimen used for biomarker assay must
be obtained non invasively. Aims of this phase are to
estimate true-positive and false-positive rates for the
clinical assay and assess the ability of the biomarker assay
to differentiate patients with HCC, in particular, those with
early HCC, from at-risk subjects, ie, patients with cirrhosis.
The biomarker assay should be simple; and its intra-assay
and interassay variability should be reported. It is
important at this phase to correlate results of the
biomarker assay with such covariates as demographics,
cause of liver disease, and other known risk factors for
HCC. The design of these studies should be case-
controlled studies. Inclusion of an adequate number of
cases in the early stage is important to determine the
diagnostic capability of the biomarker for early-stage
HCC. Controls should be patients for whom surveillance
will ultimately be applied, ie, patients with compensated
cirrhosis without known HCC. Combinations of markers
also can be evaluated at this stage. Validation of novel
biomarkers should be compared with standard methods
for HCC detection: AFP level and ultrasound. The sample
size at this phase should have sufficient power to allow for
random variation of the biomarker assay and confidence
in the results.
Phase 3: Retrospective Longitudinal Studies
Studies in this phase aim to evaluate the capacity of
the biomarker(s) to detect preclinical disease. These
studies involve the collection of specimens from a cohort
of patients with cirrhosis who are prospectively followed
up to determine whether the biomarker can detect HCC
cases before clinical diagnosis of the tumor. Samples
from patients who subsequently developed HCC are
tested retrospectively to determine whether levels of the
biomarker were elevated before HCC was diagnosed by
using available clinical tools. Studies in this phase also
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should identify such variables (covariates) as demo-
graphics, exposure to alcohol and tobacco, family history,
cause of liver disease, and prior treatment of underlying
liver disease that may affect the ability of the biomarker to
detect early HCC. Other aims include the comparison of
various biomarkers singly and in combination. Data
analysis includes determining ROC curves at different
intervals (every 6–12 month before clinical diagnosis of
HCC) to evaluate the performance of a biomarker to
identify at-risk subjects destined to develop cancer.23 No
biomarker has been identified that meets the goals of
phase 3 studies.
Phase 4: Prospective Screening Studies
Studies in phase 4 aim to determine operating
characteristics of the biomarker-based surveillance in the
relevant population by determining the cancer detection
rate and false-referral rate. Other aims would be to
evaluate the stage of the tumors detected and proportion
of patients with tumors amenable to curative treatment,
assess the feasibility and costs of implementing the
surveillance program, and monitor for tumors that may be
missed. Ideally, phase 4 studies involve randomization of
an at-risk population to surveillance with the biomarker
under study versus the standard of care. Because the
incidence rate of HCC among patients with cirrhosis is
relatively low (1%– 5%/years), a large sample size is
required. No phase 4 studies have been conducted. As
new biomarkers with promising results become available,
a phase 4 study that involves randomization of patients
with cirrhosis to surveillance with AFP level and
ultrasound versus testing for newer biomarkers would be
warranted.
Phase 5: Cancer Control Studies
Studies in phase 5 aim to determine whether
surveillance of an at-risk population by using the new
biomarker reduces the cancer burden compared with no
surveillance. Such logistics as the large sample size and
long duration required, costs of the study, acceptability
by patients and physicians, ethical considerations, and
adherence to protocol, including no surveillance in the
control group, make phase 5 studies extremely
challenging. No phase 5 study has been conducted for
HCC to date.
CONCLUSIONS
In summary, although many studies of newer markers
for HCC have been published, the existing literature has
many limitations. Most studies were underpowered. The
performance of the biomarker assays, such as
reproducibility, was seldom described. Analyses of
covariates, such as demographics and cause of liver
disease, were rarely performed. As a consequence, most
new biomarkers for HCC have remained stagnant in phase
1 or 2 studies, although some were first reported as
potential HCC markers 15 years ago. For progress to be
made in biomarker validation, federally funded
collaborative research networks should be established so
that promising biomarkers identified in phase 1 and 2
studies can be evaluated further. 
Several newer markers, including AFP-L3, des-gamma
carboxyprothrombin (DCP), golgi protein 73 (GP73),
glypican-3 (GPC3), squamous cell carcinoma antigen
(SCCA), transforming growth factor-β1 (TGFβ1), insulin-
like growth factor-II (IGF-II), insulin-like growth factor-
binding protein-2 (IGFBP-2), human cervical cancer
oncogene (HCCR), hepatocyte growth factor (HGF), KL-6
and α-acid glycoprotein (AAG) appear to be promising
and should be evaluated further in properly designed
phase 2 studies to determine their ability to detect early-
stage HCC, followed by phase 3 studies that will
retrospectively determine whether they can detect
preclinical disease. If results hold up, phase 4 studies to
assess prospectively their ability to detect early HCC,
then phase 5 studies to confirm that surveillance using
these markers can reduce morbidity and mortality from
HCC, should be conducted. This structured approach is
important because many new biomarkers are likely to be
discovered based on gene microarray, proteomics, and
tumor immunology during the next decade. <
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